PSYCHOGENIC ERECTILE DYSFUNCTION AND PHOSPHODIESTERASE INHIBITORS TYPE 5
- Autores: Pushkar D.Y.1, Segal A.S1
-
Afiliações:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- Edição: Nº 6 (2016)
- Páginas: 158-163
- Seção: Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/286641
- ID: 286641
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
In the literature, much of the attention is focused on the organic erectile dysfunction (ED) rather than on psychogenic one. This article analyses the causes and mechanisms of psychogenic ED. It outlines the issues of diagnosis, therapy and specific features of using phosphodiesterase inhibitors type 5 in the management of psychogenic ED.
Palavras-chave
Texto integral
Sobre autores
D. Pushkar
A.I. Evdokimov Moscow State University of Medicine and DentistryDepartment of Urology
A. Segal
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: aleksandr_segal@mail.ru
Dr.Med.Sci., Department of Urology
Bibliografia
- Частная сексопатология. Руководство для врачей. Том 2 / Под ред. Г.С. Васильченко. М.: Медицина, 1983. С. 15-17, 182-184.
- Мужские болезни. Книга первая / Под ред. А.А. Камалова, Н.А. Лопаткина. М.: ООО Медицинское информационное агентство, 2008. С. 231-233.
- Feldman H.A., Goldstein J., Hatzichriston D.G., Krane R.J., McKinlay J.B. Impotence and its medical and psychosocial correlates: Results the Massachusetts Male Aging Study. J. Urol. 1994;151:54-61.
- Shabsigh R., Klein L.T., Seidman S., Kaplan S.A., Lehrhoff B.J., Ritter J.S. Increased incidence of depressive symptoms in men with erectile dysfunction. J. Urol. 1998;52:848-852.
- Goldstein J., Lue T.F., Padma-Nathan H., Rosen R.C., Steers W.D., Wicker P.A. Oral Sildenafil in the treatment of erectile dysfunction. NEJM. 1998; 338: 1397-1404.
- Ефремов Е.А. Эректильная дисфункция как полиэтиологический сидром. Автореф. дисс. докт. мед. наук. М., 2011. 56 с.
Arquivos suplementares
